Literature DB >> 472662

The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant.

P M Mannucci, M T Canciani, D Mari, P Meucci.   

Abstract

An acquired inhibitor of blood coagulation, similar to that described in patients with Systemic Lupus Erythematosus (SLE), was detected during routine coagulation screening in 10 patients who did not meet the criteria for a diagnosis of SLE. The lupus-like anticoagulant (LLAC) was diagnosed on the basis of prolonged activated partial thromboplastin time (APTT) and/or prothrombin time (PT) which failed to correct when patient plasma was added to normal plasma; an additional criterion was an abnormal tissue thromboplastin inhibition test. No patient had a specific inhibitor directed against factors VIII and IX. Demonstration of LLAC was highly dependent upon the type of reagents adopted in the APTT and PT: the abnormality was detected consistently by one reagent only. One-stage assays of factors VIII and IX were characteristic of the presence of an inhibitor, showing non-parellel dose-response curves or decreased activity at low dilutions which were partially corrected at higher dilutions. Although 7 patients were free of abnormal bleeding, unequivocal signs of haemorrhagic tendency after a surgery were present in the remaining 3 patients. The findings suggest that LLAC is a non-exceptional cause of prolonged coagulation screening tests, and that it may sometimes be associated with impaired haemostasis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 472662     DOI: 10.1111/j.1600-0609.1979.tb00440.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  12 in total

Review 1.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

2.  Species specificity of lupus-like anticoagulants.

Authors:  L P Clyne
Journal:  Blut       Date:  1986-10

3.  Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

4.  Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

Authors:  N J McHugh; D A Moye; I E James; M Sampson; P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

5.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

Review 6.  Detection of lupus anticoagulants.

Authors:  M H Horellou; M M Samama
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 7.  Laboratory diagnosis of the lupus anticoagulant.

Authors:  Thomas L Ortel
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

8.  Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant.

Authors:  T K Nilsson; E Löfvenberg
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

9.  Additional factor XII (Hageman factor) deficiency in hemophilia A and in von Willebrand syndrome.

Authors:  M Barthels; J Edel; B Liese; H E Karges
Journal:  Klin Wochenschr       Date:  1982-03

10.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.